Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SA...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Tuccori, Marco, Ferraro, Sara, Convertino, Irma, Cappello, Emiliano, Valdiserra, Giulia, Blandizzi, Corrado, Maggi, Fabrizio, Focosi, Daniele
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755170/
https://ncbi.nlm.nih.gov/pubmed/33319649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2020.1854149
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars